Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8726941 | 0.85 | LTA4H (0.52) | CYP1A2CYP2D6CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7380489 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP2D6ALDH1A1CHRNA7CHRNB2 | |
| SCHEMBL5460631 | 0.82 | NR1H3 (0.46) | CYP1A2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL3758352 | 0.79 | TBXAS1 (0.56) | GAAPOLBCYP1A2CYP2D6 | |
| SCHEMBL6176772 | 0.79 | CHRNA7 (0.57) | GAAPOLBCYP1A2CYP2D6CHRNA7 | |
| SCHEMBL7041057 | 0.78 | MAOB (0.50) | ALDH1A1RAB9A | |
| SCHEMBL27613782 | 0.78 | IDO1 (0.50) | RAB9A | |
| SCHEMBL6133002 | 0.76 | NAPRT (0.48) | CYP1A2CYP2D6ALDH1A1CHRNA7CHRNB2 | |
| SCHEMBL27496388 | 0.76 | CHRNA7 (0.57) | CYP1A2CYP2D6CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL10559908 | 0.75 | CYP1A2 (0.75) | GAAPOLBCYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | claimed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | GAA 1417/4885POLB 1048/4885CYP1A2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.